Source BioScience plc (LSE: SBS), the provider of expert, quality services to the healthcare, pharma biotech and life science research sector, is pleased to announce an extension to the existing agreement to supply cytology services and automated imaging technology to Cervical Screening Wales (“CSW”).

HIGHLIGHTS

* Contract to supply liquid based cytology equipment and reagents extended for a further 12 months

* Cervical Screening Wales to extend its assessment of the FocalPoint automated cytology imaging system

* Revenue of £0.9 million over the next 12 months from these agreements

CSW has exercised its option under the existing cytology supply agreement with Source BioScience to extend the period of the agreement for a further 12 months. Under the terms of the original Official Journal of the European Union (“OJEU”) tender agreement dating back to 2004, at the end of the initial 5 year term CSW is entitled to extend the agreement for a further 12 months on substantially the same commercial terms.

CSW has also extended its assessment of the FocalPoint automated imaging platform for a further 12 months. This will enable CSW to generate a significant amount of data regarding the clinical utility of the automated imaging platform and determine its role in the future of cervical screening in

Wales.

With over 3.5 million slides manually screened for cervical cancer every year in the UK, and with each screener looking at a maximum of 30 slides per day, cytology lends itself to automation. The Government has recently concluded a Health Technology Assessment of FocalPoint as a primary screening tool and the results of that assessment are due to be published later this year.

Dr Nick Ash, Managing Director of Source BioScience said: “The decision of CSW to extend the liquid based cytology supply agreement represents a significant vote of confidence in the service and support that Source BioScience provides.

“Additionally, the extension, on a commercial basis, of the assessment of FocalPoint as an effective quality assurance tool represents a significant investment by CSW. This also demonstrates the commitment of both CSW and Source BioScience in moving forward with automated imaging. This commitment underlines the effectiveness and efficacy of the FocalPoint automated cytology system not

only as a potential primary screening platform but also as a valuable Quality Assurance tool.”